• Explore /
  • Videos & Slides
  • / Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.

Abstract Video & Slides Poster

Presenter

Ian Chau

Ian Chau, MD

Royal Marsden Hospital

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03143153

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4035)

DOI

10.1200/JCO.2022.40.16_suppl.4035

Abstract #

4035

Poster Bd #

23

Abstract Disclosures

Similar Videos & Slides

Speaker: Ken Kato, MD, PhD

Speaker: Ian Chau, MD

Speaker: Dirk Schadendorf, MD

Speaker: Ken Kato, MD, PhD